Global BCG Vaccine for Tuberculosis (TB) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global BCG Vaccine for Tuberculosis (TB) Market Research Report 2024
BCG Vaccine for Tuberculosis (TB) provides immunity or protection against tuberculosis (TB). The vaccine may be given to persons at high risk of developing TB.
According to Mr Accuracy reports new survey, global BCG Vaccine for Tuberculosis (TB) market is projected to reach US$ 549.6 million in 2029, increasing from US$ 373.9 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole BCG Vaccine for Tuberculosis (TB) market research.
The BCG (Bacillus Calmette-Guérin) vaccine for tuberculosis (TB) is driven by several key factors that influence the demand for this vaccine and its role in addressing the global TB burden
Tuberculosis PrevalenceTB remains a significant global health issue, especially in regions with high prevalence rates. The BCG vaccine is used as a preventive measure in areas with a high burden of TB cases.
TB Control and Eradication EffortsThe BCG vaccine is a critical tool in the fight against TB, supporting efforts to control the spread of the disease and eventually work towards its eradication.
Childhood Immunization ProgramsMany countries include the BCG vaccine as a part of their childhood immunization schedules to protect infants and children against TB.
Protection Against Severe FormsThe BCG vaccine is particularly effective in protecting children against severe forms of TB, such as TB meningitis and disseminated TB.
Healthcare Worker ProtectionHealthcare workers, especially those in regions with a high TB burden, may receive the BCG vaccine to reduce their risk of TB infection.
Reducing TB-Related MortalityThe BCG vaccine contributes to reducing TB-related mortality, especially in high-risk populations such as infants and individuals with compromised immune systems.
Drug-Resistant TB PreventionIn regions with drug-resistant TB strains, the BCG vaccine can help prevent the development of severe forms of TB and reduce the risk of transmission.
Global Health InitiativesOrganizations such as the World Health Organization (WHO) promote the use of the BCG vaccine as part of global TB control strategies.
High-Risk PopulationsThe BCG vaccine is often recommended for individuals at higher risk of TB exposure, such as those living in crowded or high-risk areas.
Public Health AwarenessPublic health campaigns and awareness efforts promote the importance of TB prevention through vaccination, driving demand for the BCG vaccine.
TB Elimination GoalsMany countries have set goals to eliminate TB as a public health threat. The BCG vaccine plays a role in achieving these goals.
Immunity BuildingThe BCG vaccine is known to enhance the immune response, potentially offering some level of protection against other respiratory infections.
Global Travel and MigrationTB transmission can occur through global travel and migration. The BCG vaccine may be recommended for individuals traveling to or from regions with high TB prevalence.
Research and DevelopmentOngoing research aims to improve the effectiveness and administration of the BCG vaccine, which could increase its adoption and impact.
Integration into Routine Immunization ProgramsThe integration of the BCG vaccine into routine immunization programs helps ensure that a larger portion of the population receives the vaccine.
Collaboration and FundingPartnerships between governments, international organizations, and healthcare institutions drive the availability and accessibility of the BCG vaccine.
Pandemic PreparednessThe ongoing COVID-19 pandemic has highlighted the importance of vaccine-preventable diseases, potentially increasing interest in vaccine research and development, including the BCG vaccine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG Vaccine for Tuberculosis (TB) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
AJ Vaccines
Serum Institute of India
Intervax
GSBPL
Statens Serum Institute
Biomed Lublin
ANLIS Malbran
Fundação Ataulpho de Paiva
BB-NCIPD
Taj Pharmaceuticals
Bio Farma
Microgen
Torlakinstitut
Institut Pasteur de Tunis
IVAC
Segment by Type
Immune Type
Therapy Type
Hospitals
Clinics
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The BCG Vaccine for Tuberculosis (TB) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global BCG Vaccine for Tuberculosis (TB) market is projected to reach US$ 549.6 million in 2029, increasing from US$ 373.9 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole BCG Vaccine for Tuberculosis (TB) market research.
The BCG (Bacillus Calmette-Guérin) vaccine for tuberculosis (TB) is driven by several key factors that influence the demand for this vaccine and its role in addressing the global TB burden
Tuberculosis PrevalenceTB remains a significant global health issue, especially in regions with high prevalence rates. The BCG vaccine is used as a preventive measure in areas with a high burden of TB cases.
TB Control and Eradication EffortsThe BCG vaccine is a critical tool in the fight against TB, supporting efforts to control the spread of the disease and eventually work towards its eradication.
Childhood Immunization ProgramsMany countries include the BCG vaccine as a part of their childhood immunization schedules to protect infants and children against TB.
Protection Against Severe FormsThe BCG vaccine is particularly effective in protecting children against severe forms of TB, such as TB meningitis and disseminated TB.
Healthcare Worker ProtectionHealthcare workers, especially those in regions with a high TB burden, may receive the BCG vaccine to reduce their risk of TB infection.
Reducing TB-Related MortalityThe BCG vaccine contributes to reducing TB-related mortality, especially in high-risk populations such as infants and individuals with compromised immune systems.
Drug-Resistant TB PreventionIn regions with drug-resistant TB strains, the BCG vaccine can help prevent the development of severe forms of TB and reduce the risk of transmission.
Global Health InitiativesOrganizations such as the World Health Organization (WHO) promote the use of the BCG vaccine as part of global TB control strategies.
High-Risk PopulationsThe BCG vaccine is often recommended for individuals at higher risk of TB exposure, such as those living in crowded or high-risk areas.
Public Health AwarenessPublic health campaigns and awareness efforts promote the importance of TB prevention through vaccination, driving demand for the BCG vaccine.
TB Elimination GoalsMany countries have set goals to eliminate TB as a public health threat. The BCG vaccine plays a role in achieving these goals.
Immunity BuildingThe BCG vaccine is known to enhance the immune response, potentially offering some level of protection against other respiratory infections.
Global Travel and MigrationTB transmission can occur through global travel and migration. The BCG vaccine may be recommended for individuals traveling to or from regions with high TB prevalence.
Research and DevelopmentOngoing research aims to improve the effectiveness and administration of the BCG vaccine, which could increase its adoption and impact.
Integration into Routine Immunization ProgramsThe integration of the BCG vaccine into routine immunization programs helps ensure that a larger portion of the population receives the vaccine.
Collaboration and FundingPartnerships between governments, international organizations, and healthcare institutions drive the availability and accessibility of the BCG vaccine.
Pandemic PreparednessThe ongoing COVID-19 pandemic has highlighted the importance of vaccine-preventable diseases, potentially increasing interest in vaccine research and development, including the BCG vaccine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG Vaccine for Tuberculosis (TB) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
AJ Vaccines
Serum Institute of India
Intervax
GSBPL
Statens Serum Institute
Biomed Lublin
ANLIS Malbran
Fundação Ataulpho de Paiva
BB-NCIPD
Taj Pharmaceuticals
Bio Farma
Microgen
Torlakinstitut
Institut Pasteur de Tunis
IVAC
Segment by Type
Immune Type
Therapy Type
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The BCG Vaccine for Tuberculosis (TB) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices